Prevention of cardiovascular events in diabetes.
Sigal
Ronald
R
University of Ottawa, Ottawa, Canada.
Malcolm
Janine
J
Meggison
Hilary
H
D000800:Angioplasty, Balloon; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D001629:Bezafibrate / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D001026:Coronary Artery Bypass; D003925:Diabetic Angiopathies / Q000517:prevention & control*; D015248:Gemfibrozil / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D006949:Hyperlipidemias / Q000188:drug therapy; D006973:Hypertension / Q000188:drug therapy; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors; D016540:Smoking Cessation
D000959:Antihypertensive Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D015248:Gemfibrozil; D001241:Aspirin; D001629:Bezafibrate